Literature DB >> 14502539

Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans.

Olivier Luttringer1, Frank-Peter Theil, Patrick Poulin, Anne H Schmitt-Hoffmann, Theodor Walter Guentert, Thierry Lavé.   

Abstract

The objective of this study was to use in synergy physiologically based and empirical approaches to estimate the drug-specific input parameters of PBPK models of disposition to simulate the plasma concentration-time profile of epiroprim in human. The estimated input parameters were the tissue:plasma partition coefficients (Pt:p) for distribution and the blood clearance (CL) for the in vivo conditions. Epiroprim represents a challenge for such methods, because it shows large interspecies differences in its pharmacokinetic properties. Two approaches were used to predict the human Pt:p values: the tissue composition model (TCM) and the "Arundel approach" based on the volume of distribution at steady state (Vdss) determined in vivo in the rat. CL in human was predicted by (1) conventional allometric scaling of in vivo animal clearances (CAS), (2) physiologically based direct scaling up of in vitro hepatocyte data (DSU), and (3) allometric scaling of animal intrinsic in vivo blood CL normalized by the ratios of animal:human intrinsic clearances determined in vitro with hepatocytes (NAS). The performance of prediction was assessed by comparing separately the above pharmacokinetic parameters (Vdss estimated from the Pt:p values and blood CL) with the corresponding in vivo data obtained from the plasma kinetic profiles. These input parameters were used in PBPK models, and the resulting plasma concentration-time profiles of epiroprim were compared with those observed in rat and human. Previously to the construction of the human PBPK model, a model for the rat was also developed to gain more confidence on the model structure and assumptions. Overall, using the TCM and the NAS for the parameterization of the distribution and clearance, respectively, the PBPK model gave the more accurate predictions of epiroprim's disposition in human. This study represents therefore an attractive approach, which may potentially help the clinical candidate selection. Copyright 2003 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14502539     DOI: 10.1002/jps.10461

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  15 in total

1.  Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models.

Authors:  Sabine Pilari; Wilhelm Huisinga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-07-27       Impact factor: 2.745

2.  A semiphysiologically based pharmacokinetic modeling approach to predict the dose-exposure relationship of an antiparasitic prodrug/active metabolite pair.

Authors:  Grace Zhixia Yan; Claudia N Generaux; Miyoung Yoon; Rachel B Goldsmith; Richard R Tidwell; James E Hall; Carol A Olson; Harvey J Clewell; Kim L R Brouwer; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2011-09-27       Impact factor: 3.922

3.  A novel strategy for physiologically based predictions of human pharmacokinetics.

Authors:  Hannah M Jones; Neil Parrott; Karin Jorga; Thierry Lavé
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Practical anticipation of human efficacious doses and pharmacokinetics using in vitro and preclinical in vivo data.

Authors:  Tycho Heimbach; Suresh B Lakshminarayana; Wenyu Hu; Handan He
Journal:  AAPS J       Date:  2009-08-26       Impact factor: 4.009

5.  A physiologically based pharmacokinetic model of rifampin in mice.

Authors:  Michael A Lyons; Brad Reisfeld; Raymond S H Yang; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

6.  Translational considerations for cancer nanomedicine.

Authors:  Stephan T Stern; Jennifer B Hall; Lee L Yu; Laura J Wood; Giulio F Paciotti; Lawrence Tamarkin; Stephen E Long; Scott E McNeil
Journal:  J Control Release       Date:  2010-04-10       Impact factor: 9.776

Review 7.  Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.

Authors:  Clara Hartmanshenn; Megerle Scherholz; Ioannis P Androulakis
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-09-19       Impact factor: 2.745

Review 8.  Current Approaches for Predicting Human PK for Small Molecule Development Candidates: Findings from the IQ Human PK Prediction Working Group Survey.

Authors:  Carl Petersson; Xin Zhou; Joerg Berghausen; David Cebrian; Michael Davies; Kevin DeMent; Peter Eddershaw; Arian Emami Riedmaier; Alix F Leblanc; Nenad Manveski; Punit Marathe; Panteleimon D Mavroudis; Robin McDougall; Neil Parrott; Andreas Reichel; Charles Rotter; David Tess; Laurie P Volak; Guangqing Xiao; Zheng Yang; James Baker
Journal:  AAPS J       Date:  2022-07-19       Impact factor: 3.603

9.  Physiologically based pharmacokinetics of matrine in the rat after oral administration of pure chemical and ACAPHA.

Authors:  Guanghua Gao; Francis C P Law
Journal:  Drug Metab Dispos       Date:  2009-01-08       Impact factor: 3.922

10.  Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination.

Authors:  Frédérique Fenneteau; Jacques Turgeon; Lucie Couture; Véronique Michaud; Jun Li; Fahima Nekka
Journal:  Theor Biol Med Model       Date:  2009-01-15       Impact factor: 2.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.